{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:42:45Z","timestamp":1789530165529,"version":"build-2803163510"},"reference-count":57,"publisher":"American Society of Hematology","issue":"14","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Prior studies have demonstrated that certain populations including older patients, racial\/ethnic minority groups, and women are underrepresented in clinical trials. We performed a retrospective analysis of patients with non-Hodgkin lymphoma (NHL) seen at MD Anderson Cancer Center (MDACC) to investigate the association between trial participation, race\/ethnicity, travel distance, and neighborhood socioeconomic status (nSES). Using patient addresses, we ascertained nSES variables on educational attainment, income, poverty, racial composition, and housing at the census tract (CT) level. We also performed geospatial analysis to determine the geographic distribution of clinical trial participants and distance from patient residence to MDACC. We examined 3146 consecutive adult patients with NHL seen between January 2017 and December 2020. The study cohort was predominantly male and non-Hispanic White (NHW). The most common insurance types were private insurance and Medicare; only 1.1% of patients had Medicaid. There was a high overall participation rate of 30.5%, with 20.9% enrolled in therapeutic trials. In univariate analyses, lower participation rates were associated with lower nSES including higher poverty rates and living in crowded households. Racial composition of CT was not associated with differences in trial participation. In multivariable analysis, trial participation varied significantly by histology, and participation declined nonlinearly with age in the overall, follicular lymphoma, and diffuse large B-cell lymphoma (DLBCL) models. In the DLBCL subset, Hispanic patients had lower odds of participation than White patients (odds ratio, 0.36; 95% confidence interval, 0.21-0.62; P\u00a0= .001). In our large academic cohort, race, sex, insurance type, and nSES were not associated with trial participation, whereas age and diagnosis were.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011040","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T14:54:15Z","timestamp":1712933655000},"page":"3825-3837","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9715-2577","authenticated-orcid":false,"given":"Chijioke","family":"Nze","sequence":"first","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-9117","authenticated-orcid":false,"given":"Clark R.","family":"Andersen","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Ayers","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-2337","authenticated-orcid":false,"given":"Jason","family":"Westin","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaminathan","family":"Iyer","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Pinnix","sequence":"additional","affiliation":[{"name":"3Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-452X","authenticated-orcid":false,"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[{"name":"4Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Nguyen","sequence":"additional","affiliation":[{"name":"5Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"McNeill","sequence":"additional","affiliation":[{"name":"5Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-8610","authenticated-orcid":false,"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8013-265X","authenticated-orcid":false,"given":"Kehe","family":"Zhang","sequence":"additional","affiliation":[{"name":"6Department of Biostatistics and Data Science, University of Texas Health Science Center in Houston School of Public Health, Houston, TX"},{"name":"7Center for Spatial-Temporal Modeling for Applications in Population Sciences, University of Texas Health Science Center in Houston School of Public Health, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-7965","authenticated-orcid":false,"given":"Cici X.","family":"Bauer","sequence":"additional","affiliation":[{"name":"6Department of Biostatistics and Data Science, University of Texas Health Science Center in Houston School of Public Health, Houston, TX"},{"name":"7Center for Spatial-Temporal Modeling for Applications in Population Sciences, University of Texas Health Science Center in Houston School of Public Health, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"issue":"1","key":"2024072315212444600_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2024072315212444600_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA A Cancer J Clin"},{"key":"2024072315212444600_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canep.2018.01.003","article-title":"Impact of individual and neighborhood factors on disparities in prostate cancer survival","volume":"53","author":"DeRouen","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"7","key":"2024072315212444600_bib4","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/1055-9965.EPI-15-1326","article-title":"The effect of patient and contextual characteristics on racial\/ethnic disparity in breast cancer mortality","volume":"25","author":"Sposto","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"2024072315212444600_bib5","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/1055-9965.EPI-15-0055","article-title":"Contribution of the neighborhood environment and obesity to breast cancer survival: the California breast cancer survivorship consortium","volume":"24","author":"Cheng","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"14","key":"2024072315212444600_bib6","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/cncr.29345","article-title":"The impact of neighborhood social and built environment factors across the cancer continuum: current research, methodological considerations, and future directions","volume":"121","author":"Gomez","year":"2015","journal-title":"Cancer"},{"issue":"23","key":"2024072315212444600_bib7","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2013-07-517110","article-title":"Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era","volume":"123","author":"Tao","year":"2014","journal-title":"Blood"},{"key":"2024072315212444600_bib8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.urology.2021.05.085","article-title":"Disparities in prostate cancer survival according to neighborhood archetypes, a population-based study","volume":"163","author":"DeRouen","year":"2022","journal-title":"Urology"},{"issue":"24","key":"2024072315212444600_bib9","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1002\/cncr.33861","article-title":"Individual- and neighborhood-level socioeconomic status and risk of aggressive breast cancer subtypes in a pooled cohort of women from Kaiser Permanente Northern California","volume":"127","author":"Aoki","year":"2021","journal-title":"Cancer"},{"issue":"22","key":"2024072315212444600_bib10","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-sex-and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"9","key":"2024072315212444600_bib11","first-page":"5977","article-title":"Age and race distribution in patients in phase III oncology clinical trials","volume":"12","author":"Gopishetty","year":"2020","journal-title":"Am J Transl Res"},{"issue":"9","key":"2024072315212444600_bib12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.2023020052","article-title":"Representation of the population in need for pivotal clinical trials in lymphomas","volume":"142","author":"Casey","year":"2023","journal-title":"Blood"},{"key":"2024072315212444600_bib13","article-title":"FDA to require diversity plan for clinical trials","author":"Kozlov","year":"16  2023","journal-title":"Nature"},{"issue":"11","key":"2024072315212444600_bib14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.7326\/M13-2946","article-title":"Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study","volume":"161","author":"Kind","year":"2014","journal-title":"Ann Intern Med"},{"key":"2024072315212444600_bib15","unstructured":"Epic\n          . Epic electronic medical record. 2023. Accessed 5 December 2023. https:\/\/www.epic.com\/software\/2023."},{"key":"2024072315212444600_bib16","unstructured":"US Census Bureau\n          . TIGER\/Line Geodatabases. Accessed 5 December 2023. https:\/\/www.census.gov\/geographies\/mapping-files\/time-series\/geo\/tiger-geodatabase-file.html."},{"key":"2024072315212444600_bib17","unstructured":"US Census Bureau\n          . Geocoder. C. Accessed 5 December 2023. https:\/\/geocoding.geo.census.gov\/geocoder\/."},{"key":"2024072315212444600_bib18","unstructured":"US Census Bureau\n          . American Community Survey Data. Accessed 5 December 2023. https:\/\/www.census.gov\/programs-surveys\/acs\/data.html."},{"key":"2024072315212444600_bib19","unstructured":"US Census Bureau\n          . US Decennial Census 2020. Accessed 5 December 2023. https:\/\/data.census.gov\/cedsci\/."},{"issue":"8","key":"2024072315212444600_bib20","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1023\/A:1011240019516","article-title":"Socioeconomic status and breast cancer incidence in California for different race\/ethnic groups","volume":"12","author":"Yost","year":"2001","journal-title":"Cancer Causes Control"},{"issue":"4","key":"2024072315212444600_bib21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10552-011-9736-5","article-title":"The California neighborhoods data system: a new resource for examining the impact of neighborhood characteristics on cancer incidence and outcomes in populations","volume":"22","author":"Gomez","year":"2011","journal-title":"Cancer Causes Control"},{"issue":"7","key":"2024072315212444600_bib22","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2105\/AJPH.93.7.1137","article-title":"Area deprivation and widening inequalities in US mortality, 1969-1998","volume":"93","author":"Singh","year":"2003","journal-title":"Am J Public Health"},{"issue":"4","key":"2024072315212444600_bib23","doi-asserted-by":"crossref","first-page":"pkaa011","DOI":"10.1093\/jncics\/pkaa011","article-title":"Area deprivation index and rurality in relation to lung cancer prevalence and mortality in a rural state","volume":"4","author":"Fairfield","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"3","key":"2024072315212444600_bib24","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11605-020-04754-9","article-title":"Association of socioeconomic area deprivation index with hospital readmissions after colon and rectal surgery","volume":"25","author":"Ghirimoldi","year":"2021","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"3","key":"2024072315212444600_bib25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/0269216319886215","article-title":"Examining key sociodemographic characteristics of adolescents and young adults with cancer: a post hoc analysis of the promoting resilience in stress management randomized clinical trial","volume":"34","author":"Lau","year":"2020","journal-title":"Palliat Med"},{"key":"2024072315212444600_bib26","unstructured":"Center for Health Disparities Research UoWSoMPH\n          . 2015 Area Deprivation Index, version 2.0. Accessed 15 October 2022. https:\/\/www.neighborhoodatlas.medicine.wisc.edu\/."},{"key":"2024072315212444600_bib27","unstructured":"Googleway\n          . Accesses Google Maps APIs to Retrieve Data and Plot Maps. Accessed 5 December 2022. https:\/\/CRAN.R-project.org\/package=googleway."},{"issue":"6","key":"2024072315212444600_bib28","first-page":"1","article-title":"tmap: Thematic Maps in R","volume":"84","author":"Tennekes","year":"2018","journal-title":"J\u00a0Stat Softw"},{"key":"2024072315212444600_bib29","unstructured":"R Project\n          . The R Project for Statistical Computing. Accessed 5 December 2023. https:\/\/www.r-project.org."},{"issue":"12","key":"2024072315212444600_bib30","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/88.12.812","article-title":"Representation of African-Americans, Hispanics, and whites in national cancer institute cancer treatment trials","volume":"88","author":"Tejeda","year":"1996","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8","key":"2024072315212444600_bib31","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1200\/JCO.2002.08.056","article-title":"How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials","volume":"20","author":"Sateren","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"2024072315212444600_bib32","volume-title":"Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary","author":"Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation","year":"2010"},{"issue":"9","key":"2024072315212444600_bib33","first-page":"5977","article-title":"Age and race distribution in patients in phase III oncology clinical trials","volume":"12","author":"Gopishetty","year":"2020","journal-title":"Am J Transl Res"},{"issue":"3","key":"2024072315212444600_bib34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jnci\/djy221","article-title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","volume":"111","author":"Unger","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"2024072315212444600_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jamaoncol.2015.3924","article-title":"Patient income level and cancer clinical trial participation: a prospective survey study","volume":"2","author":"Unger","year":"2016","journal-title":"JAMA Oncol"},{"issue":"9","key":"2024072315212444600_bib36","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2014.108","article-title":"The impact of socioeconomic status on access to cancer clinical trials","volume":"111","author":"Sharrocks","year":"2014","journal-title":"Br J Cancer"},{"issue":"2","key":"2024072315212444600_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/COC.0b013e3181587890","article-title":"Impact of treatment and socioeconomic status on racial disparities in survival among older women with breast cancer","volume":"31","author":"Du","year":"2008","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"2024072315212444600_bib38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/107327481602300404","article-title":"Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer","volume":"23","author":"Hamel","year":"2016","journal-title":"Cancer Control"},{"key":"2024072315212444600_bib39","unstructured":"US Census Bureau\n          . Decline in share of people without health insurance driven by increase in public coverage in 36 states. Accessed 5 December 2023. https:\/\/www.census.gov\/library\/stories\/2022\/09\/uninsured-rate-declined-in-28-states.html."},{"key":"2024072315212444600_bib40","unstructured":"US Census Bureau. American community survey S2701\n          . Selected characteristics of health insurance coverage in the Unites States. Accessed 5 December 2023. https:\/\/data.census.gov\/table\/ACSST5Y2020.S2701?q=health%20insurance%20coverage&%20g=0100000US_0500000US48201&%20=."},{"key":"2024072315212444600_bib41","unstructured":"US Census Bureau\n          . Small area health insurance estimates (SAHIE). Accessed 5 December 2023. https:\/\/www.census.gov\/data-tools\/demo\/sahie\/#\/?s_statefips=48& s_year=2020& s_stcou=48201& s_racecat=0& s_agecat=1& s_measures=ui_snc."},{"issue":"12","key":"2024072315212444600_bib42","doi-asserted-by":"crossref","first-page":"e2139593","DOI":"10.1001\/jamanetworkopen.2021.39593","article-title":"Neighborhood and individual socioeconomic disadvantage and survival among patients with nonmetastatic common cancers","volume":"4","author":"Cheng","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2024072315212444600_bib43","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2468-2667(22)00036-6","article-title":"Association of neighbourhood disadvantage and individual socioeconomic position with all-cause mortality: a longitudinal multicohort analysis","volume":"7","author":"Ribeiro","year":"2022","journal-title":"Lancet Public Health"},{"issue":"1","key":"2024072315212444600_bib44","first-page":"1351","article-title":"Individual and neighbourhood socioeconomic status increase risk of avoidable hospitalizations among Canadian adults: a retrospective cohort study of linked population health data","volume":"5","author":"Wallar","year":"2020","journal-title":"Int J Popul Data Sci"},{"issue":"3","key":"2024072315212444600_bib45","first-page":"244","article-title":"\"When offered to participate\": a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials","volume":"113","author":"Unger","year":"2021","journal-title":""},{"key":"2024072315212444600_bib46","unstructured":"National Cancer Institute\n          . March HINTS Brief 48: Clinical Trial Participation Among U.S. Adults. Accessed 5 December 2023. https:\/\/hints.cancer.gov\/publications-reports\/hints-briefs.aspx."},{"key":"2024072315212444600_bib47","first-page":"830","article-title":"Public attitudes toward participation in cancer clinical trials","volume":"21","author":"Comis","year":"2003","journal-title":""},{"issue":"4","key":"2024072315212444600_bib48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.amjsurg.2011.02.005","article-title":"Increasing minority patient participation in cancer clinical trials using oncology nurse navigation","volume":"203","author":"Holmes","year":"2012","journal-title":"Am J Surg"},{"issue":"15","key":"2024072315212444600_bib49","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1182\/bloodadvances.2022007687","article-title":"Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER\/LEO cohort analysis","volume":"6","author":"Luan","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2024072315212444600_bib50","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/bloodadvances.2021006504","article-title":"Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey","volume":"6","author":"Harkins","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"2024072315212444600_bib51","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1200\/JCO.20.01935","article-title":"Impact of organ function-based clinical trial eligibility criteria in patients with diffuse large B-cell lymphoma: who gets left behind?","volume":"39","author":"Khurana","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"2024072315212444600_bib52","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood-2022-169433","article-title":"Evaluating the Impact of Lab-Based Eligibility Criteria By Race\/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis","volume":"140","author":"Khurana","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2024072315212444600_bib53","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-20-3868","article-title":"Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group","volume":"27","author":"Magnuson","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"33","key":"2024072315212444600_bib54","first-page":"3737","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","volume":"35","author":"Kim","year":"2017","journal-title":""},{"key":"2024072315212444600_bib55","unstructured":"US Food and Drug Administration\n          . Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials; draft guidance for industry; availability. 2022. Accessed 5 December 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations."},{"key":"2024072315212444600_bib56","author":"US Food and Drug Administration","year":"2024"},{"key":"2024072315212444600_bib57","volume-title":"Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups","author":"National Academies of Sciences E, and Medicine","year":"2022"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/14\/3825\/2235696\/blooda_adv-2023-011040-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/14\/3825\/2235696\/blooda_adv-2023-011040-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T17:50:27Z","timestamp":1721757027000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/14\/3825\/515388\/Impact-of-patient-demographics-and-neighborhood"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":57,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,7,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011040","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]}}}